


PHARMACEUTICAL 2020

AGILE THERAPEUTICS INC Rank 138 of 362









PHARMACEUTICAL 2020

AGILE THERAPEUTICS INC Rank 138 of 362



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 129% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is -95%, being 208% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	35,319
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,795
Liabilities, Non-Current	0
Other Assets	177
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	252
Property and Equipment	14,044
Research and Development	9,858
Revenues	0
Selling, General and Administrative Expense	9,000

Output Variable	Value in 1000 USD
Assets	49,540
Liabilities	3,795
Expenses	18,858
Stockholders Equity	45,745
Net Income	-18,606
Comprehensive Net Income	-18,606
Economic Capital Ratio	-95%

